MYOZ3 antisense RNA 1 (MYOZ3-AS1)

MYOZ3-AS1, abbreviated from "MYOZ3 antisense RNA 1", would refer to a long noncoding antisense RNA transcript synthesized from the DNA strand opposite to the MYOZ3 (myozenin 3) gene. Such natural antisense RNAs are generally involved in regulating gene expression at multiple levels, including transcription and translation, and may act in cis (affecting the parent gene) or in trans (affecting distant genes)[1][4][7]. However, MYOZ3-AS1 itself is not established in primary databases or the literature as a distinct, functionally relevant antisense RNA, nor is it recognized as a therapeutic target. Essential context: - Natural antisense RNAs (including those named after protein-coding genes, such as "Gene-AS1") are widespread, but most, including MYOZ3-AS1, lack direct functional or clinical annotation[1][4][6][7]. - Well-studied antisense RNAs (like BACE1-AS or MALAT1) have demonstrated disease associations, but MYOZ3-AS1 does not appear in authoritative reviews of antisense RNAs implicated in therapy, biomarker development, or as drug targets[6][7]. - The convention of naming antisense transcripts as "[Gene symbol]-AS1" is used in genomics, but the existence or relevance of each is not guaranteed unless shown by experimental evidence. Summary: There is no robust evidence that MYOZ3-AS1 is a therapeutically relevant molecular target, nor is it a clearly recognized or annotated RNA molecule in current public resources. Most references to antisense RNAs pertain to general regulatory functions, not specific to MYOZ3-AS1. Any further claims about its roles, biomarkers, or druggability would be speculative and unsupported by current literature.